Home
Service
Small Molecule Services
Macromolecular Services
In vitro ADME Screening Services
Animal Experimental Services
Daily Chemical Testing Service
Our Clients
COOPERATION CUSTOMERS
Apply immediately
Articles
Article published
Academic research
Guarantee
Quality Assurance
Organizational guarantee
Process assurance
Information Assurance
Technical support
News
Guochen Dynamic
Industry News
About Us
Company Profile
Enterprise culture
Development process
Contact Us
Over 3 billion yuan! Corning Jerry and Shiyao Group Reach Cooperation on HER2 Dual-level ADC
On September 29, Corning Jerry announced that it has entered into a license agreement ("License Agreement") with Zimant Biotechnology, a wholly-owned subsidiary of CSPC, to develop, sell, promise to sell and commercialize JSKN003 (a HER2-targeted dual-site ADC) in mainland China (excluding Hong Kong, Macau or Taiwan) for the treatment of cancer-related indications.
29
2024
/
09
Eli Lilly buys an injection factory! GLP-1 production capacity "ceiling", putting pressure on Novo Nordisk?
Recently, Eli Lilly announced that it had reached a final agreement with sterile drug manufacturer Nexus Pharmaceuticals to acquire the latter's injectable drug manufacturing plant in Pleasant Prairie, Wisconsin, USA. Eli Lilly believes that this acquisition will further expand its global manufacturing network for injectable products and support the market's increased demand for the company's related drugs. Eli Lilly estimates that the plant may begin production by the end of 2025.
27
04
Analysis of the registration key points of biosynthetic and traditional microbial fermentation APIs
Synthetic biology can be understood as the engineering of biology, which is equivalent to deconstructing various basic biological components and then reconstructing biological systems with desired functions to produce various target substances. McKinsey predicts that by 2025, the economic value of synthetic biology and biomanufacturing may reach as high as 100 billion US dollars, and 60% of global material production in the future can be achieved through synthetic biology manufacturing. As a cutting-edge interdisciplinary subject, the scope of application of synthetic biology basically covers most fields, and has broad application prospects in the fields of medicine, health, manufacturing, agriculture, etc.
26
Leading the nuclear medicine track, opening the road of RLT commitment to China
Innovative drug research and development involves multiple fields and links, including efficacy, pharmacokinetic, safety evaluation, clinical, etc. Each link has its own special requirements and challenges. To improve R&D efficiency and quality and accelerate the process of listing, non-clinical and translational medicine research plays a vital role in biopharmaceutical R&D.
16
Quantitative analysis of clinical biological samples of generic and innovative drugs
The pharmaceutical industry is related to national life, health and safety, and is highly valued worldwide. With the vigorous development of the global biomedical industry, the wave of innovation is one after another, and the scale of investment in pharmaceutical research and development is growing. CRO(Contract Research Organization, or contract research organization) industry market penetration is increasing, the industry development speed is obvious.
22
2023
Study on the whole set of drug preclinical application service and pharmacotoxicokinetics
Guided by the R & D needs of enterprises, gather large-scale instrument service resources across the country, closely link the platform service chain with the enterprise innovation chain, and effectively reduce the R & D costs of small and medium-sized enterprises. Through the four measures of "policy guidance, market configuration, model innovation, and service integration" At the same time, we will build a first-class science and technology public service platform based in Suzhou, serving the Yangtze River Delta, and radiating the whole country, which is open, networked and public.
In vivo ADME study
In 2022, China's in vivo ADME market capacity is 100 million yuan (RMB), and the global in vivo ADME market capacity is 100 million yuan. It is expected that the global in vivo ADME market capacity will grow at a compound annual growth rate of% during the forecast period and reach 100 million yuan in 2028.
